25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking PrEP regimen being subsidised via the Pharmaceutical Benefits Scheme.
Researchers point to the increasing number of HIV-positive Australians starting early antiretroviral treatment to prevent its development and spread.
The latest surveillance report from the Kirby Institute estimated 27,545 people were living with HIV in 2017, and a recent decline in new diagnoses showed the potential for pre-exposure prophylaxis (PrEP) to protect gay men from infection.
Read The Australian article